METHODS FOR BETTER DELIVERY OF ACTIVE AGENTS TO TUMORS

1 . A method of treating a subject with a disease comprising one or more tumors by administering one or more bioactive agents to the one or more tumors comprising:

(a) applying one or more delivery devices having between 2 and 50,000 delivery structures to one or more sites of a skin of a subject comprising blood vasculature and lymphatic vasculature, wherein the delivery device contacts one or more layers of epidermis with one or more reversible permeability enhancers comprising a chemical, physical or electrical permeability enhancer that induces reversible increase in the permeability of one or more barrier cells of the epidermis to at least the one or more bioactive agents;

(b) administering a total liquid dosage in between 2 and 50,000 sub-doses of the one or more bioactive agents at a controlled administration flow rate through the delivery device;

wherein each sub-dose of the one or more bioactive agents is independently administered, in an administering step, to a plurality of independent depths within the epidermis prior to any subsequent diffusion or movement of the one or more bioactive agents within the epidermis; wherein the plurality of independent depths within the epidermis is from about 1 μm to about 500 μm beyond a most superficial surface layer of the epidermis of the subject, and

wherein following the administering step, the one or more bioactive agents moves or diffuses deeper through the epidermis through a basal layer of the epidermis and into at least a portion of underlying viable dermis to achieve an uptake of a portion of the one or more bioactive agents by one or more susceptible blood capillary plexus or lymphatic capillary plexus, wherein administration of one or more bioactive agents achieves a dermal interstitial fluid pressure in the portion of underlying viable dermis beneath a site of administration of about 1 mmHg to about 15 mmHg;

wherein after administration and uptake, the one or more bioactive agents circulates through the blood vasculature or lymphatic vasculature to one or more tumors; and

wherein a greater concentration of the one or more bioactive agents is delivered to the one or more tumors compared to intravenous, intradermal, or subcutaneous delivery using an identical one or more bioactive agents.

2 . The method according to claim 1 , wherein the total liquid dosage of the one or more bioactive agents administered to the plurality of independent depths within the epidermis comprises administration to a depth within at least a portion of non-viable epidermis and/or at least a portion of viable epidermis.

3 . The method according to claim 1 , wherein the total liquid dosage of the one or more bioactive agents is administered to a plurality of depths within the epidermis consisting only of one or more viable epidermal layers and not a non-viable epidermal layer.

4 . The method according to claim 3 , wherein the plurality of depths within the viable epidermis is from about 1 μm to about 250 μm beyond a deepest non-viable epidermal layer but still within the viable epidermis.

5 . The method according to claim 1 , wherein the average of the plurality of independent depths exhibits a combined average sub-dose delivery depth within the epidermis of about 70 μm to about 175 μm beyond the most superficial surface layer of the epidermis.

6 . The method according to claim 1 , wherein the plurality of independent depths has a combined average depth of administration within the epidermis, wherein each independently administered sub-dose is at a depth within the epidermis that is deeper, shallower, or the same.

7 . The method according to claim 1 , wherein a frequency of each of the independent sub-dose administration depth within the viable and/or non-viable epidermis exhibits a Gaussian distribution of depths.

8 . The method according to claim 1 , wherein the delivery device comprises an array comprising between 2 and 50,000 of the delivery structures in fluid communication with the one or more bioactive agents in a liquid carrier vehicle,

wherein the delivery device comprises a means for controlling the administration flow rate including at least one component selected from the group consisting of a pump, a fluid delivery rate controller, a syringe, a pen, an elastomer membrane, or any combination thereof;

wherein the delivery structures comprise a means for penetrating at least a most superficial layer of the epidermis; and

wherein the one or more bioactive agents in the liquid carrier vehicle is delivered by the delivery structures to the plurality of independent depths within a viable epidermis of the subject, thereby administering between 2 and 50,000 sub-doses of the one or more bioactive agents.

9 . The method according to claim 8 , wherein the one or more bioactive agents is administered at a controlled administration flow rate of about 0.01 μl/hr to about 100 μl/hr per delivery structure of the delivery structures.

10 . The method according to claim 8 , wherein the delivery structures comprise a standard or nonstandard geometric shape.

11 . The method according to claim 1 , wherein the controlled administration flow rate of the one or more bioactive agents to the plurality of depths within the epidermis is from about 0.02 μl/hr/cm 2 to about 50,000 μl/hr/cm 2 based on the total surface area of a delivery device that is in contact with the skin of the subject.

12 . The method according to claim 11 , wherein the physical permeability enhancers comprises a nanostructured or nanotopography surface.

13 . The method according to claim 1 , wherein the delivery structures comprise needles.

14 . The method according to claim 1 , wherein the one or more bioactive agents is delivered to a tissue volume of the epidermis encompassing the one or more bioactive agents prior to any subsequent diffusion or movement of the one or more bioactive agents within the epidermis of about 0.7 mm3 to about 2,500 mm 3 .

15 . The method according to claim 1 , wherein a concentration of the one or more bioactive agents within the one or more tumors is about 1.25 fold to about 50 fold more compared to the intravenous, intradermal, or subcutaneous delivery using the identical one or more bioactive agents.

16 . The method according to claim 1 , wherein the bioactive agent is useful for retarding progression of, delaying onset of, prophylaxis of, amelioration of or reducing symptoms of the disease comprising the one or more tumors.

17 . The method according to claim 1 , wherein the one or more bioactive agents is continuously administered to a subject for a time period of about 0.1 hours to about 96 hours.